The therapeutic potential of melatonin in neurological disorders

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 1, 2009, Pages 60-64

  Bhavsar, Bhavini ^a   Farooq, Muhammad U ^b   Bhatt, Archit ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b East Lansing   (United States)

Author keywords

Melatonin; Neurological disorders

Indexed keywords

MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PLACEBO;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENCEPHALOMYELITIS; HEADACHE; HUMAN; LEARNING DISORDER; MENINGITIS; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEIZURE; SLEEP DISORDER; TARDIVE DYSKINESIA;

EID: 70349215378     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409787003001     Document Type: Review

References (91)

1. Claustrat B, Loisy C, Brun J, Beorchia S, Arnaud JL, Chazot G. Nocturnal plasma melatonin levels in migraine: A preliminary report. Headache 1989; 29: 242-245.
2. Shavali S, Ho B, Govitrapong P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. Brain Res Bull 2005 30; 64: 471-479.
3. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-411.
4. Peres MF, Stiles MA, Oshinsky M, Rozen TD. Remitting form of hemicrania continua with seasonal pattern. Headache 2001; 41: 592-594.
5. Peres MF, Zukerman E, da Cunha TF, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004; 63: 757.
6. Spears RC. Hemicrania continua: A case in which a patient experienced complete relief on melatonin. Headache 2006; 46: 524-527.
7. Rozen TD. Melatonin responsive hemicrania continua. Headache 2006; 46: 1203-1204.
8. Rozen TD. Melatonin as treatment for idiopathic stabbing headache. Neurology 2003; 61: 865-866.
9. Leone M, D'Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia 1996; 16: 494-496.
10. Nagtegaal JE, Smits MG, Swart AC, Kerkhof GA, van der Meer YG. Melatonin-responsive headache in delayed sleep phase syndrome: Preliminary observations. Headache 1998; 38: 303-307.
11. Reiter RJ, Morgan WW. Attempts to characterize the convulsive response of parathyroidectomized rats to pineal gland removal. Physiol Behav 1972; 9: 203-208.
12. Mevissen M, Ebert U. Anticonvulsant effects of melatonin in amygdala-kindled rats. Neurosci Lett 1998; 257: 13-16.
13. Costa-Lotufo LV, Fonteles MM, Lima IS, et al. Attenuating effects of melatonin on pilocarpine-induced seizures in rats. Comp Biochem Physiol C Toxicol Pharmacol 2002; 131: 521-529.
14. Yildirim M, Marangoz C. Anticonvulsant effects of melatonin on penicillin-induced epileptiform activity in rats. Brain Res 2006; 1099: 183-188.
15. Fauteck J, Schmidt H, Lerchl A, Kurlemann G, Wittkowski W. Melatonin in epilepsy: First results of replacement therapy and first clinical results. Biol Signals Recept 1999; 8: 105-110.
16. Peled N, Shorer Z, Peled E, Pillar G. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001; 42: 1208-1210.
17. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ, et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: Two years experience. J Pineal Res 1997; 23: 97-105.
18. Sandyk R, Tsagas N, Anninos PA. Melatonin as a proconvulsive hormone in humans. Int J Neurosci 1992; 63: 125-135.
19. Stewart LS, Leung LS. Hippocampal melatonin receptors modulate seizure threshold. Epilepsia 2005; 46: 473-480.
20. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998 25; 351: 1254.
21. Jones C, Huyton M, Hindley D. Melatonin and epilepsy. Arch Dis Child 2005; 90: 1203-1204.
22. Borowicz KK, Kaminski R, Gasior M, Kleinrok Z, Czuczwar SJ. Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol 1999; 9: 185-190.
23. MacLeod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41.
24. Lee EJ, Lee MY, Chen HY, et al. Melatonin attenuates gray and white matter damage in a mouse model of transient focal cerebral ischemia. J Pineal Res 2005; 38: 42-52.
25. Tutunculer F, Eskiocak S, Basaran UN, Ekuklu G, Ayvaz S, Vatansever U. The protective role of melatonin in experimental hypoxic brain damage. Pediatr Int 2005; 47: 434-439.
26. Duan Q, Wang Z, Lu T, Chen J, Wang X. Comparison of 6-hydroxylmelatonin or melatonin in protecting neurons against ischemia/reperfusion-mediated injury. J Pineal Res 2006; 41: 351-357.
27. Letechipia-Vallejo G, Lopez-Loeza E, Espinoza-Gonzalez V, et al. Long-term morphological and functional evaluation of the neuroprotective effects of post-ischemic treatment with melatonin in rats. J Pineal Res 2007; 42: 138-146.
28. Lee MY, Kuan YH, Chen HY, et al. Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats. J Pineal Res 2007; 42: 297-309.
29. Li XJ, Zhang LM, Gu L, Zhang AZ, Sun FJ. Melatonin decreases production of the hydroxyl radical during cerebral ischemia-reperfusion. Acta Pharmacol Sin 1997; 18: 394-396.
30. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: A significant role for melatonin. J Pineal Res 2004; 36: 1-9.
31. Kilic E, Kilic U, Reiter RJ, Bassetti CL, Hermann DM. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: Role of endothelin converting enzyme-1. J Pineal Res 2004; 37: 247-251.
32. Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM. Signal transduction pathways involved in melatonin-induced neuro-protection after focal cerebral ischemia in mice. J Pineal Res 2005; 38: 67-71.
33. Joo JY, Uz T, Manev H. Opposite effects of pinealectomy and melatonin administration on brain damage following cerebral focal ischemia in rat. Restor Neurol Neurosci 1998; 13: 185-191.
34. Kilic E, Ozdemir YG, Bolay H, Kelestimur H, Dalkara T. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J Cereb Blood Flow Metab 1999; 19: 511-516.
35. Cho S, Joh TH, Baik HH, Dibinis C, Volpe BT. Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res 1997; 755: 335-338.
36. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 2005; 23: 104-117.
37. Chen TY, Lee MY, Chen HY, et al. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res 2006; 40: 242-250.
38. Aydin MV, Caner H, Sen O, et al. Effect of melatonin on cerebral vasospasm following experimental subarachnoid hemorrhage. Neurol Res 2005; 27: 77-82.
39. Kim YS, Joo WS, Jin BK, Cho YH, Baik HH, Park CW. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 1998 13; 9: 2387-2390.
40. Sharma R, McMillan CR, Tenn CC, Niles LP. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 2006; 12(1068): 230-236.
41. Singh S, Ahmed R, Sagar RK, Krishana B. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat. Indian J Med Res 2006; 124: 419-426.
42. Antolin I, Mayo JC, Sainz RM, et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain res 2002; 943: 163-173.
43. Ortiz GG, Crespo-Lopez ME, Moran-Moguel C, Garcia JJ, Reiter RJ, Acuna-Castroviejo D. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett 2001; 22: 101-108.
44. Khaldy H, Escames G, Leon J, Bikjdaouene L, Acuna-Castroviejo D. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging 2003; 24: 491-500.
45. Chen ST, Chuang JI, Hong MH, Li EI. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002; 32: 262-269.
46. Jin BK, Shin DY, Jeong MY, et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 1998; 245: 61-64.
47. Joo WS, Jin BK, Park CW, Maeng SH, Kim YS. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 1998; 9: 4123-4126.
48. Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60: PL23-29.
49. Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 2007; 42: 247-253.
50. Sandyk R. Pineal melatonin functions: Possible relevance to Parkinson's disease. Int J Neurosci 1990; 50: 37-53.
51. Miller JW, Selhub J, Joseph JA. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 1996; 21: 241-249.
52. Khaldy H, Escames G, Leon J, Vives F, Luna JD, Acuna-Castroviejo D. Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000; 29: 100-107.
53. Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004; 36: 25-32.
54. Iacovitti L, Stull ND, Johnston K. Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res 1997; 768: 317-326.
55. Mayo JC, Sainz RM, Antolin I, Rodriguez C. Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res 1999; 818: 221-227.
56. Sandyk R, Kay SR. The relationship of pineal calcification and melatonin secretion to the pathophysiology of tardive dyskinesia and Tourette's syndrome. Int J Neurosci 1991; 58: 215-247.
57. Sandyk R. The relationship of pineal calcification to subtypes of tardive dyskinesia in bipolar patients. Int J Neurosci 1990; 54: 307-313.
58. Sandyk R. The association of pineal calcification with drug-induced dystonic movements. Int J Neurosci 1990; 53: 217-222.
59. Sandyk R, Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. Int J Neurosci 1989; 48: 303-308.
60. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 2000; 61: 556-558.
61. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58: 1049-1052.
62. Minors DS, Rabbitt PM, Worthington H, Waterhouse JM. Variation in meals and sleep-activity patterns in aged subjects; its relevance to circadian rhythm studies. Chronobiol Int 1989; 6: 139-146.
63. Van Gool WA, Mirmiran M. Aging and circadian rhythms. Prog Brain Res 1986; 70: 255-277.
64. Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 1990; 528: 170-174.
65. Uchida K, Okamoto N, Ohara K, Morita Y. Daily rhythm of serum melatonin in patients with dementia of the degenerate type. Brain Res 1996; 717(1-2): 154-159.
66. Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab 1999; 84: 323-327.
67. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 1999; 45: 417-421.
68. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Daily rhythm of serum melatonin levels and effect of light exposure in patients with dementia of the Alzheimer's type. Biol Psychiatry 1999; 45: 1646-1652.
69. Ferrari E, Arcaini A, Gornati R, et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol; 35: 1239-1250.
70. Wu YH, Zhou JN, Balesar R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol 2006; 499: 897-910.
71. Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2007; 28: 1239-1247.
72. Brunner P, Sozer-Topcular N, Jockers R, et al. Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease. Eur J Histochem 2006; 50: 311-316.
73. Jean-Louis G, Zizi F, von Gizycki H, Taub H. Effects of melatonin in two individuals with Alzheimer's disease. Perceptual and motor skills. 1998; 87: 331-339.
74. [74] Lopez BD, Debeljuk L. Prenatal melatonin and its interaction with tachykinins in the hypothalamic-pituitary-gonadal axis. Reprod Fertil Dev 2007; 19: 443-451.
75. Wong, Y. H., Ho, M. K. C., Hu, Y., New, D. C., He, X., Pang, H.: WO08092292A1 (2008).
76. Gerber J, Lotz M, Ebert S, et al. Melatonin is neuroprotective in experimental Streptococcus pneumoniae meningitis. J Infect Dis. 2005; 191: 783-790.
77. Spreer A, Gerber J, Baake D, Hanssen M, Huether G, Nau R. Antiinflammatory but no neuroprotective effects of melatonin under clinical treatment conditions in rabbit models of bacterial meningitis. J Neurosci Res 2006; 84: 1575-1579.
78. Valero N, MarinaEspina L, Bonilla E, Mosquera J. Melatonin decreases nitric oxide production and lipid peroxidation and increases interleukin-1 beta in the brain of mice infected by the Venezuelan equine encephalomyelitis virus. J Pineal Res 2007; 42: 107-112.
79. Escames G, Lopez LC, Tapias V, et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006; 40: 71-78.
80. Vijayalaxmi TCR Jr, Reiter RJ, Herman TS. Melatonin: From basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-2601.
81. Martin V, Herrera F, Carrera-Gonzalez P, et al. Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 2006; 66: 1081-1088.
82. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV, Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant, geroprotector and anticarcinogen. Biochim Biophys Acta 2006; 1757: 573-589.
83. Yang QH, Xu JN, Xu RK, Pang SF. Antiproliferative effects of melatonin on the growth of rat pituitary prolactin-secreting tumor cells in vitro. J Pineal Res 2007; 42: 172-179.
84. Wion-Barbot N, Berger F, Wion D. Should we control the pineal status of patients following brain radiotherapy? J Neurooncol 2005; 74: 335.
85. Clement, K., Chaudhur, S.: US20080254121 (2008).
86. Bilodeau, M. T., Nanda, K.K., Trotter, B.W.: WO2008124030A1 (2008).
87. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: A meta-analysis. Sleep Med Rev 2005; 9: 41-50.
88. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: Meta-analysis. Br Med J 2006; 332: 385-393.
89. Arendt J. Does melatonin improve sleep? Efficacy of melatonin. Br Med J 2006; 332: 550.
90. Laakso ML, Lindblom N, Leinonen L, Kaski M. Endogenous melatonin predicts efficacy of exogenous melatonin in consolidation of fragmented wrist-activity rhythm of adult patients with developmental brain disorders: A double blind, placebo-controlled, crossover study. Sleep Med 2007; 8(2): 222-239.
91. Buscemi N, Vandermeer B, Pandya R, et al. Melatonin for Treatment of Sleep Disorders. Summary, Evidence Report/Technology Assessment: Number 108. AHRQ Publication Number 05-E002-1, November 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/ clinic/epcsums/melatsum.htm